Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 4;11(1):130.
doi: 10.3390/biomedicines11010130.

Seventy Years of Antipsychotic Development: A Critical Review

Affiliations
Review

Seventy Years of Antipsychotic Development: A Critical Review

Mujeeb U Shad. Biomedicines. .

Abstract

Since the mid-1950s discovery of the first effective antipsychotic medications (APM), we have only been able to improve the tolerability but not the overall efficacy of currently available APMs, as reflected by effectiveness trials in Europe and the United States. This inability to develop more effective APMs is attributable to multiple factors, including failure to create and use assessment tools to assess core symptom domains in schizophrenia, move beyond the dopaminergic hypothesis and to develop "me too" drugs, imposing ill-defined research domain criteria, and lacking federal funding for clinical trials. The classification of APMs is also confusing, including second-generation, partial agonists, and multimodal APMs in the same class of APMs, despite significant differences in their mechanisms of action. Other factors stagnating drug development include inadequate sample sizes to address heterogeneity, lack of statistical measures correlating with clinical significance, using the atheoretical basis of psychiatric diagnoses, failure to control placebo response, and high cost of newer and perhaps more tolerable APMs. Furthermore, there has been a failure to develop early predictors of antipsychotic response and various tools to optimize an APM response. Finally, some mental health providers are also responsible for the suboptimal use of APMs, by using excessive maintenance doses, often with irrational polypharmacy, further compromising effectiveness and medication adherence. However, some bright spots in antipsychotic development include improved tolerability of APMs and long-acting injectables to address the high prevalence of medication nonadherence. This review critically reviews 70 years of antipsychotic development, the reasons behind the failure to develop more effective APMs, and suggestions for future direction.

Keywords: antipsychotic; critical; development; review; seventy; years.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Extrapyramidal Symptoms (EPS) with antipsychotic medications.
Figure 2
Figure 2
Hyperprolactinemia with antipsychotic medications.
Figure 3
Figure 3
Weight gain with antipsychotic medications.
Figure 4
Figure 4
QTc prolongation with antipsychotic medications.

References

    1. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261. - DOI - PubMed
    1. Allsopp K., Read J., Corcoran R., Kinderman P. Heterogeneity in psychiatric diagnostic classification. Psychiatry Res. 2019;279:15–22. doi: 10.1016/j.psychres.2019.07.005. - DOI - PubMed
    1. Escobar J.I. An insider’s view of the new diagnostic and statistical manual of North American psychiatry (DSM-5) Colomb. Médica. 2013;44:129–131. doi: 10.25100/cm.v44i2.1361. - DOI - PMC - PubMed
    1. Markowitz J.C., Milrod B.L. Lost in Translation: The Value of Psychiatric Clinical Trials. J. Clin. Psychiatry. 2022;83:43385. doi: 10.4088/JCP.22com14647. - DOI - PubMed
    1. Shad M.U. High-Dose Therapy in Treatment-Refractory Psychosis: A Retrospective Study. Prim. Care Companion CNS Disord. 2022;24:44191. doi: 10.4088/PCC.21m03214. - DOI - PubMed

LinkOut - more resources